Speed Medical SAE

Speed Medical SAE has a liquidity ratio of 0.61, indicating that its current assets are less than its current liabilities, which suggests a potential liquidity risk. The company's debt-to-equity ratio is 0.7, which is relatively low, but the negative net cash position after subtracting total debt raises concerns about its short-term financial stability.

The company's profitability is negative, with a return on equity of -3.92% and a return on assets of -1.9%, which are below the industry norms for a healthcare services and equipment provider. These figures indicate that the company is not generating sufficient returns to cover its costs and is not performing well compared to its peers.

Speed Medical SAE's revenue is concentrated in a single geographic region, primarily Egypt, which increases its exposure to local economic and political risks. The company does not disclose segment-specific revenue, making it difficult to assess the performance of different parts of its business.

The company's growth trajectory is uncertain, as it has reported negative operating and net income. The outlook for the current fiscal year does not indicate a significant improvement in revenue or profitability. The company's capital expenditure is negative, suggesting a reduction in investment in new projects or assets.

The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, suggesting that it may need to raise additional capital or restructure its debt to maintain operations.

Recent events, such as the company's financial performance and capital structure, suggest that it is facing challenges in maintaining profitability and liquidity. The company's financial statements and disclosures do not indicate any major recent events that would significantly impact its operations or financial position.

Free cash flow improved by 38% year-over-year, indicating a potential stabilization in cash generation despite ongoing operational losses.

Net income showed a slight 4.8% year-over-year improvement, suggesting a marginal reduction in the magnitude of recent financial losses.

Long-term debt decreased significantly to 123.5 million EGP, reflecting a reduction in leverage compared to previous fiscal periods.

Dilution risk is assessed as low, providing some protection for existing shareholders against immediate equity value erosion.

Credit risk is flagged as high, indicating significant concerns regarding the company's ability to meet its financial obligations.

Return on equity stands at -3.9%, ranking in the bottom quartile compared to the 4.6% median of the healthcare cohort.

Liquidity risk is assessed as medium, suggesting potential challenges in meeting short-term financial requirements amidst negative cash flows.

Revenue EGP 120.0M, −67,1% YoY; Operating income −184,7% YoY.

• ▍Revenue EGP 120.0M, −67,1% YoY
• ▍Operating income −184,7% YoY
• ▍Net income −207,7% YoY
• ▍Free cash flow −15,7% YoY
• ▍Net margin -121.8%

Revenue EGP 365.2M, +110,0% YoY; Operating income +138,8% YoY.

• ▍Revenue EGP 365.2M, +110,0% YoY
• ▍Operating income +138,8% YoY
• ▍Net income +71,4% YoY
• ▍Free cash flow −258,2% YoY
• ▍Net margin 37.2%

Revenue EGP 173.9M; Operating income EGP 67.7M.

• ▍Revenue EGP 173.9M
• ▍Operating income EGP 67.7M
• ▍Net margin 45.6%